EHA 2022 | TakeAim Lymphoma: emavusertib + ibrutinib in R/R hematological malignancies
Erel Joffe, MD, MSc, Tel Aviv Medical Center, Tel Aviv, Israel, and Memorial Sloan Kettering Cancer Center, New York, NY, comments on the mechanism of action of emavusertib, an IRAK4 inhibitor, and highlights the results of TakeAim Lymphoma, a Phase I study evaluating this drug in combination with ibrutinib in patients with relapsed/refractory (R/R) hematological malignancies (NCT03328078). Whilst the study reported promising efficacy results with two partial responders and two complete responders, it also reported occurrences of transient rhabdomyolysis. TakeAim Leukemia (NCT04278768), another study evaluating emavusertib in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) revealed that patients with specific spliceosome mutations may be more sensitive to this drug. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Principle investigator on CA-4948 clinical trial for evaluation in lymphoma
Epizyme – advisory board
AstraZeneca – advisory board
